Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Rachael A. Jankowich
Observed name:
Rachael Jankowich
Institution:
Urovant Sciences GmbH (Switzerland)
Observed institutions:
Duke University,
Duke Medical Center,
Tenax Therapeutics (United States),
Urovant Sciences GmbH (Switzerland),
Duke Clinical Research Institute
OpenAlex ID:
A5033972840
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery
2017
·
Rajendra H. Mehta
, Jeffrey D. Leimberger
, et al.
·
New England Journal of Medicine
·
329
PDF
Bisphenol A, Bisphenol S, and 4-Hydroxyphenyl 4-Isoprooxyphenylsulfone (BPSIP) in Urine and Blood of Cashiers
2015
·
Kristina A. Thayer
, Kyla W. Taylor
, et al.
·
Environmental Health Perspectives
·
226
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
2020
·
David Staskin
, Jeffrey Frankel
, et al.
·
The Journal of Urology
·
141
Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery
2019
·
Sean van Diepen
, Rajendra H. Mehta
, et al.
·
Journal of Thoracic and Cardiovascular Surgery
·
61
PDF
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
2020
·
David Staskin
, Jeffrey Frankel
, et al.
·
The Journal of Urology
·
50
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
2021
·
Susann Varano
, David Staskin
, et al.
·
Drugs & Aging
·
32
PDF
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial
2016
·
Rajendra H. Mehta
, Sean Van Diepen
, et al.
·
American Heart Journal
·
29
Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
2020
·
Jeffrey Frankel
, Susann Varano
, et al.
·
International Journal of Clinical Practice
·
23
PDF
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
2022
·
David Staskin
, Jeffrey Frankel
, et al.
·
International Journal of Clinical Practice
·
15
PDF
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
2021
·
Jeffrey Frankel
, David Staskin
, et al.
·
Advances in Therapy
·
13
PDF
Pd21-01 Once-daily Vibegron 75 Mg for Overactive Bladder (oab): Double-blind 52-week Results From an Extension Study of the International Phase 3 Trial (empowur)
2020
·
David Staskin*
, Jeffrey Frankel
, et al.
·
The Journal of Urology
·
3
Pd21-02 Efficacy of Once-daily Vibegron 75 Mg for Overactive Bladder (oab) in Older Patients: the Empowur Randomized, International, Phase 3 Study
2020
·
Jeffrey Frankel*
, David Staskin
, et al.
·
The Journal of Urology
·
2
Mp63-15 Vibegron for the Treatment of Patients With Dry Overactive Bladder: a Subgroup Analysis From the Empowur Trial
2021
·
David Staskin
, Jeffrey Frankel
, et al.
·
The Journal of Urology
·
1
Once-Daily Vibegron 75 mg Demonstrates Statistically Significant Benefits on Key Secondary Endpoints Including Quality of Life in Patients With OAB: Data From an International Phase 3 Trial (EMPOWUR)
2019
·
David R. Staskin
, Susann Varano
, et al.
·
Neurourology and Urodynamics
·
1
Reply by Authors
2021
·
David Staskin
, Jeffrey Frankel
, et al.
·
The Journal of Urology
Reply by Authors
2020
·
David Staskin
, Jeffrey Frankel
, et al.
·
The Journal of Urology
Lba-02 International Phase 3, Double-blind, Placebo- and Active (tolterodine)-controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder: Empowur
2019
·
David Staskin*
, Jeffrey Frankel
, et al.
·
The Journal of Urology
Show more works
View as search
Works count:
17
Citation count:
926
H-index:
10
I10-index:
10
Year
Topic
Type